Venture investing in early-stage companies hinges on spotting transformative technologies before they become hyped. To support this, we built the MeSH Counter: an R-based tool that tracks monthly frequencies of specific terms in PubMed, allowing us to visualize trends in the life sciences. Publication trends are not the same as investment signals, yet the MeSH Counter can help efficiently map the research landscape, so investors can prioritize deeper, human-led diligence.
Belgian startup BIO INX develops bioinks to 3D print cells into living tissues and organ-on-chip technologies. The company is working with academic and industry partners to develop products ranging from artificial corneas to cartilage. The aim: translate academic ideas into to real-world applications with tangible patient impact.
As a sector, agrifood biotech has enormous potential to improve the sustainability, resilience, and productivity of our food systems. Yet many promising innovations still fail to reach the market, often because they are not sufficiently aligned with real-world needs or adoption barriers. The B-Trust project aims to involve end-users from the start, to help make agrifood R&D more relevant, equitable, and impactful.
On 29 January 2026, 400 Belgian healthcare stakeholders — hospital executives, policymakers, and innovators — gathered in Brussels to help shape the future of healthcare. The objective was to connect hospital needs with the innovative technologies developed by Belgian companies. Two projects were honored during the event’s Innovation Awards: Baby Detect and SIM BLOOD.
We are all familiar with global viruses: The flu shows up every year across the world, and not long ago we collectively experienced the SARS-CoV-2 pandemic. Now, a neglected tropical disease is joining this club of viruses without borders. Dengue — also known as break-bone fever — is currently one of the world’s fastest spreading viral diseases, with more than half of the global population already at risk.
An increasing number of PhD students are concerned about their career prospects. Currently, only around 5-10% of PhD graduates remain in academia — the vast majority have to navigate an unfamiliar job market, where industry demand for their highly educated profiles appears to be in decline. Is a PhD still the best route to professional success? And what can students do to prepare themselves?
Europe’s healthtech pipeline was on full display at the HealthTech Investor Summit 2025 in Utrecht, with the regions brightest rising stars in the spotlight. From surgical robotics and implantable devices to bioelectronics and next-generation diagnostics, here are the pitching companies that stood out to both the judges and audience.
In Antwerp, a unique cohort of volunteers is helping to solve one of the world's most urgent medical challenges: the early detection of cognitive decline. While the study is local, its implications are global — providing the long-term data needed to understand the hidden years of decline in Alzheimer's disease and other forms of dementia, to enable early diagnosis and intervention.
Behind the vivid colors of our phone screens and smartwatches lies a world too small for the naked eye to see. But scientists at the University of Antwerp have developed a new method to analyze small changes in the atomic arrangement of the nanomaterials in these kinds of digital displays, which is key to creating stable and efficient materials for solar cells or electronics in the future.
In the past two years, a rapid succession of FDA policy shifts has fundamentally reshaped the regulatory landscape. These changes have created uncertainty for biotech companies around the world — lengthening development timelines, increasing demands for upfront capital, and amplifying modality-specific risks. European investors should now consider explicit regulatory strategies as essential to the success of their portfolio.
Venture investing in early-stage companies hinges on spotting transformative technologies before they become hyped. To support this, we built the MeSH Counter: an R-based tool that tracks monthly frequencies of specific terms in PubMed, allowing us to visualize trends in the life sciences. Publication trends are not the same as investment signals, yet the MeSH Counter can help efficiently map the research landscape, so investors can prioritize deeper, human-led diligence.
Belgian startup BIO INX develops bioinks to 3D print cells into living tissues and organ-on-chip technologies. The company is working with academic and industry partners to develop products ranging from artificial corneas to cartilage. The aim: translate academic ideas into to real-world applications with tangible patient impact.
As a sector, agrifood biotech has enormous potential to improve the sustainability, resilience, and productivity of our food systems. Yet many promising innovations still fail to reach the market, often because they are not sufficiently aligned with real-world needs or adoption barriers. The B-Trust project aims to involve end-users from the start, to help make agrifood R&D more relevant, equitable, and impactful.
On 29 January 2026, 400 Belgian healthcare stakeholders — hospital executives, policymakers, and innovators — gathered in Brussels to help shape the future of healthcare. The objective was to connect hospital needs with the innovative technologies developed by Belgian companies. Two projects were honored during the event’s Innovation Awards: Baby Detect and SIM BLOOD.
We are all familiar with global viruses: The flu shows up every year across the world, and not long ago we collectively experienced the SARS-CoV-2 pandemic. Now, a neglected tropical disease is joining this club of viruses without borders. Dengue — also known as break-bone fever — is currently one of the world’s fastest spreading viral diseases, with more than half of the global population already at risk.
An increasing number of PhD students are concerned about their career prospects. Currently, only around 5-10% of PhD graduates remain in academia — the vast majority have to navigate an unfamiliar job market, where industry demand for their highly educated profiles appears to be in decline. Is a PhD still the best route to professional success? And what can students do to prepare themselves?
Europe’s healthtech pipeline was on full display at the HealthTech Investor Summit 2025 in Utrecht, with the regions brightest rising stars in the spotlight. From surgical robotics and implantable devices to bioelectronics and next-generation diagnostics, here are the pitching companies that stood out to both the judges and audience.
In Antwerp, a unique cohort of volunteers is helping to solve one of the world's most urgent medical challenges: the early detection of cognitive decline. While the study is local, its implications are global — providing the long-term data needed to understand the hidden years of decline in Alzheimer's disease and other forms of dementia, to enable early diagnosis and intervention.
Behind the vivid colors of our phone screens and smartwatches lies a world too small for the naked eye to see. But scientists at the University of Antwerp have developed a new method to analyze small changes in the atomic arrangement of the nanomaterials in these kinds of digital displays, which is key to creating stable and efficient materials for solar cells or electronics in the future.
In the past two years, a rapid succession of FDA policy shifts has fundamentally reshaped the regulatory landscape. These changes have created uncertainty for biotech companies around the world — lengthening development timelines, increasing demands for upfront capital, and amplifying modality-specific risks. European investors should now consider explicit regulatory strategies as essential to the success of their portfolio.